KLRK1 and central nervous system cancer: The ligands of NKG2D include MICA, MICB and ULBP1-6 (32, 33) and are upregulated in multiple tumor entities like acute myeloid leukemia, ovarian-, breast-, lung-cancer, melanoma, glioma and STS (17).